Recursion Pharmaceuticals, Inc. has grown revenue 3.1% a year over three years and 44% a year over five. Revenue growth, 3-year annual rate: +3.1% (Biotechnology median +17%). Revenue growth, 5-year rate: +44%, growth has slowed since the five-year average. Years of annual history on file: 7, FY2019 to FY2025, as filed.

RXRXRecursion Pharmaceuticals, Inc.

Healthcare

$4.36-11% 1Y

$4.36

$2.8452 weeks$6.79

Is it growing?

Watch

Growth is fading: revenue shrinking (−15% year on year) and operating margin narrowing (−185.9 points).

2 to watch, 1 without data

Revenue trend−15% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +44% a year.

Margin direction−185.9 points operating

Trailing-twelve-month operating margin, -1844.4% now against -1658.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RXRX growing?

Recursion Pharmaceuticals, Inc. has grown revenue 3.1% a year over three years and 44% a year over five.

+3.1%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +44%
Revenue growth, 5-year rate · +3.1% over three · growth has slowed since the five-year average
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›